Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (9): 88-96.doi: 10.6040/j.issn.1671-7554.0.2019.790

Previous Articles    

Analysis of risk factors and drug resistance of Acinetobacter baumannii in patients with chronic obstructive pulmonary disease

ZHANG Ning1, YANG Yan2, LI Rui2, YIN Yunhong2, LI Hao2, QU Yiqing2   

  1. 1. Department of Respiratory and Critical Care Medicine A Ward, Shandong Chest Hospital, Jinan 250013, Shandong, China;
    2. Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2022-09-27

PDF (PC)

112

Abstract: Objective To explore the risk factor of Acinetobacter baumannii(AB)infection and drug resistance in patients with chronic obstructive pulmonary disease(COPD)in order to provide a theoretical basis for treating AB infection in COPD patients. Methods The clinical data of inpatients treated during 2012 and 2015 were collected from departments of respiratory and respiratory intensive care unit, and 308 AB positive patients were selected according to the exclusion criteria. Drug-resistant bacteria and drug resistance were detected in 308 AB positive cases and 91 COPD cases with AB. A case control study was performed in 144 COPD patients, including 72 AB positive and 72 AB negative cases. 山 东 大 学 学 报 (医 学 版)57卷9期 -张宁,等.慢阻肺患者感染鲍曼不动杆菌危险因素及耐药性分析 \=- The risk factors associated with AB infection were determined with binary logistic regression analysis. Results (1) Single factor analysis showed that age, recent history of hospitalization, history of glucocorticoid and antibiotics use, invasive operations, chronic diseases, classification of lung function and frequency of exacerbations were statistically significant (P<0.05). Multivariate Logistic regression showed that invasive operation (OR=3.725, 95% CI=2.642-9.534), recent history of hospitalization (OR=3.417, 95%CI=1.412-8.515), classification of lung function (OR=2.835, 95%CI=1.012-9.853), history of glucocorticoid use (OR=2.815, 95%CI=1.328-9.045), chronic disease (OR=2.136, 95%CI=1.023-8.146), history of antibiotic use(OR=2.326, 95%CI=1.145-7.134), frequency of exacerbations (OR=2.823, 95%CI=1.012-9.853), age (OR=1.756, 95%CI=1.003-7.035) were independent risk factors of AB infection (P<0.05). (2) Drug resistance tests of AB positive patients showed that cefepime had the highest drug resistance rate(79.2%), while tegacycline had the lowest drug resistance rate(20.1%). (3) Compared to non-COPD patients, COPD patients with AB had higher resistance rates to imipenem(86.8% vs 59.4%), cefepime(93.4% vs 73.2%), levofloxacin(82.4% vs 57.6%), cefoperazone sulbactam(49.4% vs 29.0%)and tegacycline(27.5% vs 17.1%). The differences were statistically significant (P<0.05). Conclusion Chronic diseases, invasive operation, recent history of hospitalization, history of glucocorticoid and antibiotic use and classification of lung function are independent risk factors for COPD patients infected with AB. Compared with non-COPD patients with lower respiratory tract infection of AB, COPD patients with AB have higher resistance rate to common clinical antibiotics.

Key words: Chronic obstructive pulmonary disease, Acinetobacter baumannii, Drug resistance, Risk factors, Multivariate logistic regression analysis

CLC Number: 

  • R574
[1] Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetbacter baumannii [J]. Nat Rev Microbiol, 2007, 5(12): 939-951.
[2] 刘又宁, 曹彬, 王辉, 等. 中国九城市成人医院获得性肺炎微生物与临床特点调查[J]. 中华结核和呼吸杂志, 2012, 35(4): 739.
[3] Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections [J]. Lancet Infect Dis, 2008, 8(12): 751-762.
[4] Zheng YL, Wan YF, Zhou LY, et a1. Risk factors and mortality of patients with nosocomial earbapenem-resistant Acinetobacter baumannii pneumonia [J]. Am J Infect Control, 2013, 41(7): 59-63.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华内科杂志, 2013, 46(3): 254-261.
[6] Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[EB/OL].(2006-11-19)[2009-12] http://www.Goldcopd.com.
[7] MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease [J]. Proc Am Thorac Soc, 2008, 5(4): 530-535.
[8] 王冬梅. 慢性阻塞性肺疾病急性加重期痰培养及药敏结果分析[J]. 大家健康, 2015, 9(7): 49-50.
[9] Ye F, He LX, Cai BQ, et al. Spectrum and antimicrobial resistance of common pathogenic bacteria isolated from patients with acute exacerbation of chronic obstructive pulmonary disease in mainland of China [J]. Chin Med J(Engl), 2013, 126(12): 2207 -2214.
[10] Diaz E, Planas K, Rello J. Infection associated with the use of assisted-ventilation devices [J]. Enferm Infecc Microbiol Clin, 2008, 26(7): 465-470.
[11] 中华人民共和国卫生部.医院感染诊断标准(试行)[J]. 现代实用医学, 2003, 15(7): 460-465.
[12] 汪复, 张婴元.实用抗感染治疗学[M].北京: 人民卫生出版社, 2004: 7-8.
[13] Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen [J]. Clin Microbiol Rev, 2008, 21(3): 538-582.
[14] 陈佰义, 何礼贤, 胡必杰, 等. 中国AB感染诊治与防控专家共识[J]. 中华医学杂志, 2012, 92(2): 76-82.
[15] Xiao-Min X, You-Fen F, Wei-Yun F, et al. Antibiotic resistance determinants of a group of multidrug-resistant Acinetobacter baumannii in China[J]. J Antibiot(Tokyo), 2014, 67(6):439-444.
[16] 王辉, 俞云松, 王明贵, 等. 替加环素体外药敏试验操作规程专家共识[J]. 中华检验医学杂志, 2013, 36(7): 584-587.
[17] Levin AS. Multi-resistant Acinetobacter infections: A role for sulbactam combinations in overcoming an emerging worldwide problem [J]. Clin Microbiol Infect, 2002, 8(3): 144-153.
[18] 李春辉. 医疗机构耐药菌MDR、XDR、PD的国际标准化定义专家建议(草案)[J]. 中国感染控制杂志, 2011, 12(3): 238-240.
[19] 张辉, 张小江, 徐英春, 等. 2012年中国CHINET不动杆菌属细菌耐药性监测[J]. 中国感染与化疗杂志, 2014, 14(5): 392-397.
[20] 胡付品, 朱德妹, 汪复, 等. 2014年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志, 2015, 15(5): 401-410.
[21] 俞云松. 多药耐药AB-21世纪革兰阴性菌的“MRSA”[J]. 中华临床感染病杂志, 2009, 2(7): 65-68.
[22] Bacakoglu F, Korkmaz Ekren P, Ta?瘙塂bakan MS, et al. Multidrug-resistant acinetobacter baumannii infection in respiratory intensive care unit [J]. Mikrobiyol Bul, 2009, 43(4): 575-585.
[23] Wroblewska MM, Sawicka-Grzelak A, Marchel H, et al. Biofilm production by clinical strains of Acin, etobacter baumannii isolated from patients hospitalized in two tertiary care hospitals [J]. FEMS Immunol Med Microbiol, 2008, 53(1): 140-144.
[24] Munoz-Price LS, Carling P, Cleary T, et al. Control of a two-decade endemic situation with carbapenem-resistant Acinetobacter baumannii: electronic dissemination of a bundle of interventions [J]. Am J Infect Control, 2014, 42(5): 466-471.
[25] Parameswaran GI, Sethi S. Pseudomonas infection in chronic obstructive pulmonary disease [J]. Future Microbiol, 2012, 7(10): 1129-1132.
[26] Morgan DJ, Liang SY, Smith CL, et a1. Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers [J]. Infect Ctrl Hosp Epidemiol, 2010, 31(7): 716-721.
[27] Efrati S, Deutsch I, Antonelli M, et al. Vantilator-associated pneumonia: current status and future recommendations [J]. J Clin Monit Comput, 2010, 24(2): 161-168.
[28] Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study [J]. Antimicrob Agents Chemother, 2004, 48(1): 224-228.
[29] Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy[J].Chest, 2007, 131(1): 9-19.
[30] Rumbo C, Gato E, Lopez M, et al. Contribution of efflux pumps,porins,and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii [J]. Antimicrob Agents Chemother, 2013, 57(11): 5247-5257.
[31] 习慧明, 徐英春, 朱德妹, 等. 2010年中国CHINETAB耐药性监测[J]. 中国感染与化疗杂志, 2012, 12(2): 98-104.
[32] 张辉, 张小江, 徐英春, 等. 2011年中国CHINET不动杆菌属细菌耐药性监测[J]. 中国感染与化疗杂志, 2013, 13(5): 342-348.
[33] Rodriguez-Hernandez MJ, Pachon J, Pichardo C,et al. Imipenem,doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia [J]. J Antimicrob Chemother, 2000, 45(4): 493-501.
[1] GE Li-Juan, JIN Rui-Feng, WANG Ji-Wen, HU Xin-Sheng, LIKun. Association between the C1236T polymorphism in multi-drug resistance gene 1 and response to antiepileptic drug treatment in epileptic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 99-102.
[2] YAO Xue, LU Ranran, SUN Shuling, GAO Cuiping, XIAO Ru, WANG Shuhui. Establishment of a risk prediction scoring model for nosocomial infection in rheumatic heart disease patients after valve replacement surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 90-96.
[3] LI Yan, LIU Jing, LI Juan, YANG Qiuhong. Clinical characteristics and placental pathology of bloodstream infection in 50 pregnant women [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 48-54.
[4] Chunfang HA,Ruyue LI. Research progress of drug resistance in ovarian cancer and targeted therapy strategy [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 117-123.
[5] Jianhua JU,Zhenye YANG,Qinglian LI,Ya'nan HAN,Yanqing LI,Yijun QIAO,Hu YANG,Huaran ZHANG. Advances on drugs derived from microbial sources and future perspectives [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 43-50,63.
[6] CHEN Liyu, XIAO Juan, LYU Xianzhong, DUAN Baomin, HONG Fanzhen. Risk factors influencing prognosis of lower extremity deep vein thrombosis in pregnant and parturient women [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 38-42.
[7] Haipeng SI,Wencan ZHANG,Le LI,Xin ZHOU. Research advances on risk factors, diagnosis and treatment of Kümmell's disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 25-32.
[8] XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110.
[9] CHEN Qingyi, ZHANG Xuan, WANG Juan, SUN Jiwei, CAO Danfeng, CAO fenglin. Risk factors and cumulative effects of suicidal ideation in pregnant women [J]. Journal of Shandong University (Health Sciences), 2021, 59(1): 91-94.
[10] FU Zhenmei, MA Mingze. Expression of P-glycoprotein in the colonic mucosa of ulcerative colitis patients and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 54-59.
[11] CHEN Linlin, YI Shaolei, WANG Weizong, LI Zhan, ZHANG Yong, ZHANG Yujiao,REN Manyi, XIE Xinxing, LIU Tongbao, HOU Yinglong. Risk factors of recurrent atrial fibrillation after radiofrequency catheter ablation [J]. Journal of Shandong University (Health Sciences), 2019, 57(3): 49-57.
[12] YU Zhigang, ZHOU Fei. Management of non-lactational infectious breast abscesses [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 1-5.
[13] TIAN Zhongyan, LI Yuqian, LIU Xiaotian, SHI Yuanyuan, ZHANG Haiqing, ZHANG Xia, QIAN Xinling, YIN Lei, ZHAO Jingzhi, WANG Chongjian. Relationship between PSMD6 gene rs831571 locus polymorphism and the susceptibility of T2DM: a case-control study [J]. Journal of Shandong University (Health Sciences), 2018, 56(7): 51-56.
[14] DING Yanfei, YANG Zhuoxin, ZHENG Wenwen, YUAN Wenjie, GAO Yanjing. Risk factors of portal vein thrombosis in patients with liver cirrhosis [J]. Journal of Shandong University (Health Sciences), 2018, 56(12): 13-18.
[15] WANG Chuanxin. Research progress of exosomes biomarkers in tumor development [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 18-23.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd